|
Post by dreamboatcruise on Sept 12, 2017 17:14:57 GMT -5
mango ... one has to consider pancreas is creating squirts of insulin every five minutes or so, so unlike Afrezza it isn't a one shot deal when you eat. Endogenous insulin released in hexamer form is not as fast as inhaling Afrezza in monomer form. Afrezza initiates the first phase insulin response so dang fast it acts as an exogenous regulator of glucose homeostasis—the tight regulation of blood sugar. Perhaps the most meaningful and useful invention humankind has seen in a long while. When are you starting the clock ticking for endogenous insulin to make this timing comparison? It is clear that the timing of Afrezza should start when you inhale. Your pancreas might be triggered to start releasing some insulin merely when you start anticipating eating, as the other parts of your body have anticipatory response. Is the timing starting then, when you take the first bite, when your BG first starts going up from the food, or something else? Point is the time to peak of endogenous is an ill defined concept. If faster than your pancreas is something that has clinical benefit, one can always predose with exogenous and shift the peak arbitrarily ahead of the pancreas peak. Not sure that's a big deal, however. The signalling to the liver as it has evolved over millennia seems to work just fine in healthy people. A bit of a stretch to start claiming Afrezza is better than not having diabetes... it surely isn't.
|
|
|
Post by itellthefuture777 on Sept 12, 2017 17:42:24 GMT -5
Endogenous insulin released in hexamer form is not as fast as inhaling Afrezza in monomer form. Afrezza initiates the first phase insulin response so dang fast it acts as an exogenous regulator of glucose homeostasis—the tight regulation of blood sugar. Perhaps the most meaningful and useful invention humankind has seen in a long while. When are you starting the clock ticking for endogenous insulin to make this timing comparison? It is clear that the timing of Afrezza should start when you inhale. Your pancreas might be triggered to start releasing some insulin merely when you start anticipating eating, as the other parts of your body have anticipatory response. Is the timing starting then, when you take the first bite, when your BG first starts going up from the food, or something else? Point is the time to peak of endogenous is an ill defined concept. If faster than your pancreas is something that has clinical benefit, one can always predose with exogenous and shift the peak arbitrarily ahead of the pancreas peak. Not sure that's a big deal, however. The signalling to the liver as it has evolved over millennia seems to work just fine in healthy people. A bit of a stretch to start claiming Afrezza is better than not having diabetes... it surely isn't. Afrezza takes the load off the pancreas...seems the earlier used..the better imo
|
|
|
Post by dreamboatcruise on Sept 12, 2017 18:00:41 GMT -5
When are you starting the clock ticking for endogenous insulin to make this timing comparison? It is clear that the timing of Afrezza should start when you inhale. Your pancreas might be triggered to start releasing some insulin merely when you start anticipating eating, as the other parts of your body have anticipatory response. Is the timing starting then, when you take the first bite, when your BG first starts going up from the food, or something else? Point is the time to peak of endogenous is an ill defined concept. If faster than your pancreas is something that has clinical benefit, one can always predose with exogenous and shift the peak arbitrarily ahead of the pancreas peak. Not sure that's a big deal, however. The signalling to the liver as it has evolved over millennia seems to work just fine in healthy people. A bit of a stretch to start claiming Afrezza is better than not having diabetes... it surely isn't. Afrezza takes the load off the pancreas...seems the earlier used..the better imo Yes, I think most everyone invested in MNKD agrees with that. We're all just waiting for the medical practitioners, and payers, to come around to that view. Neither of those constituencies will be convinced easily. A shame we haven't had money to start an early intervention trial. Hopefully we will someday.
|
|